Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
Background: Nonalcoholic fatty liver disease (NAFLD) comprises hepatic alterations with increased lipid accumulation (steatosis) without or with inflammation (nonalcoholic steatohepatitis, NASH) and/or fibrosis in the absence of other causes of liver disease. NAFLD is developing as a burgeoning heal...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-08-01
|
Series: | Molecular Metabolism |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2212877820301964 |
id |
doaj-f449521e45f940ff9f00c9994474ff01 |
---|---|
record_format |
Article |
spelling |
doaj-f449521e45f940ff9f00c9994474ff012021-07-23T04:48:47ZengElsevierMolecular Metabolism2212-87782021-08-0150101122Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humansKalliopi Pafili0Michael Roden1Institute of Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research, Düsseldorf, Germany; German Center for Diabetes Research, München-Neuherberg, GermanyInstitute of Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research, Düsseldorf, Germany; German Center for Diabetes Research, München-Neuherberg, Germany; Division of Endocrinology and Diabetology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany; Corresponding author. Division of Endocrinology and Diabetology, Medical Faculty, Heinrich-Heine University, Düsseldorf, c/o German Diabetes Center at Heinrich-Heine University, Auf dem Hennekamp 65; 40225 Düsseldorf, Germany. Fax: +49 211 3382 691.Background: Nonalcoholic fatty liver disease (NAFLD) comprises hepatic alterations with increased lipid accumulation (steatosis) without or with inflammation (nonalcoholic steatohepatitis, NASH) and/or fibrosis in the absence of other causes of liver disease. NAFLD is developing as a burgeoning health challenge, mainly due to the worldwide obesity and diabetes epidemics. Scope of review: This review summarizes the knowledge on the pathogenesis underlying NAFLD by focusing on studies in humans and on hypercaloric nutrition, including effects of saturated fat and fructose, as well as adipose tissue dysfunction, leading to hepatic lipotoxicity, abnormal mitochondrial function, and oxidative stress, and highlights intestinal dysbiosis. These mechanisms are discussed in the context of current treatments targeting metabolic pathways and the results of related clinical trials. Major conclusions: Recent studies have provided evidence that certain conditions, for example, the severe insulin-resistant diabetes (SIRD) subgroup (cluster) and the presence of an increasing number of gene variants, seem to predispose for excessive risk of NAFLD and its accelerated progression. Recent clinical trials have been frequently unsuccessful in halting or preventing NAFLD progression, perhaps partly due to including unselected cohorts in later stages of NAFLD. On the basis of this literature review, this study proposed screening in individuals with the highest genetic or acquired risk of disease progression, for example, the SIRD subgroup, and developing treatment concepts targeting the earliest pathophysiolgical alterations, namely, adipocyte dysfunction and insulin resistance.http://www.sciencedirect.com/science/article/pii/S2212877820301964Fatty liverLipotoxicityInflammationFibrosisInsulin resistanceClinical trials |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kalliopi Pafili Michael Roden |
spellingShingle |
Kalliopi Pafili Michael Roden Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans Molecular Metabolism Fatty liver Lipotoxicity Inflammation Fibrosis Insulin resistance Clinical trials |
author_facet |
Kalliopi Pafili Michael Roden |
author_sort |
Kalliopi Pafili |
title |
Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans |
title_short |
Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans |
title_full |
Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans |
title_fullStr |
Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans |
title_full_unstemmed |
Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans |
title_sort |
nonalcoholic fatty liver disease (nafld) from pathogenesis to treatment concepts in humans |
publisher |
Elsevier |
series |
Molecular Metabolism |
issn |
2212-8778 |
publishDate |
2021-08-01 |
description |
Background: Nonalcoholic fatty liver disease (NAFLD) comprises hepatic alterations with increased lipid accumulation (steatosis) without or with inflammation (nonalcoholic steatohepatitis, NASH) and/or fibrosis in the absence of other causes of liver disease. NAFLD is developing as a burgeoning health challenge, mainly due to the worldwide obesity and diabetes epidemics. Scope of review: This review summarizes the knowledge on the pathogenesis underlying NAFLD by focusing on studies in humans and on hypercaloric nutrition, including effects of saturated fat and fructose, as well as adipose tissue dysfunction, leading to hepatic lipotoxicity, abnormal mitochondrial function, and oxidative stress, and highlights intestinal dysbiosis. These mechanisms are discussed in the context of current treatments targeting metabolic pathways and the results of related clinical trials. Major conclusions: Recent studies have provided evidence that certain conditions, for example, the severe insulin-resistant diabetes (SIRD) subgroup (cluster) and the presence of an increasing number of gene variants, seem to predispose for excessive risk of NAFLD and its accelerated progression. Recent clinical trials have been frequently unsuccessful in halting or preventing NAFLD progression, perhaps partly due to including unselected cohorts in later stages of NAFLD. On the basis of this literature review, this study proposed screening in individuals with the highest genetic or acquired risk of disease progression, for example, the SIRD subgroup, and developing treatment concepts targeting the earliest pathophysiolgical alterations, namely, adipocyte dysfunction and insulin resistance. |
topic |
Fatty liver Lipotoxicity Inflammation Fibrosis Insulin resistance Clinical trials |
url |
http://www.sciencedirect.com/science/article/pii/S2212877820301964 |
work_keys_str_mv |
AT kalliopipafili nonalcoholicfattyliverdiseasenafldfrompathogenesistotreatmentconceptsinhumans AT michaelroden nonalcoholicfattyliverdiseasenafldfrompathogenesistotreatmentconceptsinhumans |
_version_ |
1721290696567029760 |